The national supply of the cancer drug cisplatin now exceeds demand, FDA Commissioner Robert Cailiff, MD, said June 28. 

InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within…

An inhalable drug treatment for chronic obstructive pulmonary disease received FDA-approval June 26, drugmaker Verona Pharma announced.

Mark Cuban Cost Plus Drug Co. will serve as a wholesale drug distributor for all 71 hospitals affiliated with Community Health Systems, the organizations announced June 27. 

Between 2014 and 2024, prescription medication prices have increased 37%, according to a GoodRx, which launched a prescription cost tracker June 26. 

Mail-ordered prescriptions were supposed to be cheaper, but these medications are costing more than those picked up at pharmacy counters, The Wall Street Journal reported June 25. 

A year after multiple popular oncology treatments were in short supply, U.S. cancer centers are still struggling to stock enough cancer therapies. 

Glenmark Pharmaceuticals Inc., USA, is voluntarily recalling 144 batches of potassium chloride extended-release capsules because of failed dissolution, the FDA said June 25.

Novo Nordisk is planning to build a $4.1 billion manufacturing plant in Clayton, N.C., to help meet demand for its blockbuster drugs Ozempic and Wegovy.

"Alexa, what are the side effects of amoxicillin?"